Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200-Day Moving Average of $2.94

Vaxart, Inc. (NASDAQ:VXRTGet Rating) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.94 and traded as low as $1.30. Vaxart shares last traded at $1.30, with a volume of 1,951,455 shares trading hands.

Wall Street Analysts Forecast Growth

Several research firms have commented on VXRT. Brookline Capital Management restated a “buy” rating on shares of Vaxart in a report on Monday, October 3rd. Cantor Fitzgerald decreased their target price on Vaxart from $11.00 to $8.00 and set an “overweight” rating for the company in a report on Friday, September 2nd.

Vaxart Stock Performance

The stock has a fifty day simple moving average of $1.80 and a two-hundred day simple moving average of $2.94. The stock has a market cap of $170.62 million, a PE ratio of -1.57 and a beta of 0.80.

Hedge Funds Weigh In On Vaxart

A number of institutional investors have recently made changes to their positions in VXRT. Two Sigma Advisers LP acquired a new stake in shares of Vaxart during the 3rd quarter valued at approximately $34,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Vaxart during the 2nd quarter valued at approximately $37,000. Beacon Capital Management LLC raised its position in shares of Vaxart by 116.3% during the 3rd quarter. Beacon Capital Management LLC now owns 10,814 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 5,814 shares in the last quarter. Atom Investors LP acquired a new stake in shares of Vaxart during the 3rd quarter valued at approximately $39,000. Finally, Moors & Cabot Inc. raised its position in shares of Vaxart by 100.0% during the 3rd quarter. Moors & Cabot Inc. now owns 20,000 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 10,000 shares in the last quarter. 35.15% of the stock is owned by institutional investors and hedge funds.

About Vaxart

(Get Rating)

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.

Further Reading

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.